Balancing Transparency and Privacy in Individual-Level Clinical Data Sharing

Introduction: The Need and the Risk

Individual-level data (ILD), also known as participant-level data, is considered the gold standard for secondary analyses, meta-analyses, and reproducibility of clinical trial results. Yet, sharing such granular datasets introduces significant legal, regulatory, and ethical complexities. While transparency is a scientific imperative, it must be balanced with the rights of trial participants, especially regarding confidentiality, consent, and re-identification risk.

With global regulatory regimes such as the EU General Data Protection Regulation (GDPR) and the U.S. HIPAA Privacy Rule, sponsors must adopt rigorous frameworks before sharing ILD. This article explores key considerations and provides a roadmap for responsible sharing.

What Constitutes Individual-Level Data?

Individual-level data refers to the raw, de-identified records of each participant, including baseline demographics, treatment responses, adverse events, lab values, and timelines. It is distinct from aggregate data summaries commonly published in journals.

While de-identification removes obvious identifiers (e.g., name, date of birth), residual risk of re-identification remains—especially when combined with external datasets (e.g., genomic data or social data).

Legal Frameworks Impacting ILD Sharing

• ➤ HIPAA (USA): Defines 18 personal identifiers and outlines two methods for de-identification: Expert Determination and Safe Harbor.
• ➤ GDPR (EU): Treats pseudonymized data as personal data and imposes strict conditions for cross-border sharing.
• ➤ Data Protection Act (UK), and Personal Data Protection Bill (India) also apply to international trials.
• ➤ Local IRBs and Ethics Committees may impose additional requirements for consent and access control.

Checklist: Legal Readiness for ILD Sharing

Requirement	Met?
Informed consent allows data reuse
Data de-identified using HIPAA or GDPR methods
Data Use Agreement (DUA) in place
Cross-border data transfer mechanisms validated
Repository access control protocols implemented

Informed Consent and Ethical Transparency

Consent forms must transparently outline potential future use of participant data. This includes:

• ➤ Reuse for secondary research or meta-analysis
• ➤ Uploading data to public or controlled repositories
• ➤ Use in regulatory decision-making or AI models

Omission of these clauses may render data sharing legally and ethically impermissible—even if data are de-identified.

Common Consent Pitfalls

Even well-designed consent forms may fall short if they:

• ❌ Use vague language like “data may be shared with researchers”
• ❌ Fail to define what “anonymized” means
• ❌ Do not specify duration or scope of data sharing

Clear, plain-language disclosures are essential, especially for lay participants and vulnerable populations.

Controlled Access: An Ethical Middle Path

To mitigate risks, many sponsors and data platforms use controlled access models. These include:

• ➤ Requiring researcher credentials and institutional affiliation
• ➤ Mandatory Data Use Agreements (DUAs)
• ➤ Ethics review of secondary analysis proposals
• ➤ Monitoring for policy violations or re-identification attempts

Examples include Vivli, CSDR, and the YODA Project.

Sample Table: Public vs Controlled Data Access

Feature	Open Access	Controlled Access
Researcher Screening	❌
Ethics Approval Required	❌
DUA Enforced	❌
Audit Trail	❌

Risks of Re-Identification

Studies show that as few as 3 demographic fields (e.g., zip code, birthdate, gender) can re-identify up to 87% of U.S. citizens. Risks increase with:

• ❌ Small population trials (e.g., rare diseases)
• ❌ Genomic or facial imaging data
• ❌ Linkage to social or public databases

Thus, anonymization alone does not absolve sponsors from risk. Ethical governance, legal agreements, and technical safeguards are all needed.

Regulatory Enforcement and Case Examples

In 2022, a U.S. academic institution was fined for sharing partially de-identified data that violated HIPAA Safe Harbor provisions. In the EU, the Irish Data Protection Commission investigated a pharma company for lack of consent clarity in a cross-border trial. These highlight the growing scrutiny around data sharing compliance.

Best Practices for Sponsors and CROs

• ➤ Engage Data Protection Officers (DPOs) early in protocol design
• ➤ Validate consent language with IRBs
• ➤ Use expert consultation for de-identification techniques
• ➤ Maintain a Data Sharing Risk Register with mitigation actions

Conclusion: Ethics and Law Must Evolve Together

The push for open science must be met with proportional ethical and legal safeguards. Sharing individual-level data is essential to scientific advancement, but not at the expense of participant trust. With harmonized consent language, smart access controls, and active governance, stakeholders can walk the fine line between transparency and protection.

Navigating GDPR Compliance in International Clinical Trials

Introduction to GDPR in Clinical Research

The General Data Protection Regulation (GDPR) is the cornerstone of data privacy legislation in the European Union. Any clinical trial that processes data from EU residents, regardless of where the sponsor, CRO, or site is located, must comply with GDPR. The regulation introduces strict requirements for:

• Lawful basis for data processing
• Data subject rights (access, erasure, rectification)
• Data minimization and retention
• Cross-border data transfers
• Data breach notifications

Non-compliance may result in penalties of up to 4% of annual global turnover or €20 million—whichever is higher.

Lawful Basis for Data Collection and Processing

Under GDPR, personal data processing must be based on a legal ground. For clinical trials, this is typically:

• Article 6(1)(e): Public interest in the area of public health or research
• Article 9(2)(j): Processing of special categories of data for scientific research

Although informed consent is obtained from trial participants, it is not the legal basis under GDPR for processing. This distinction is critical during inspections.

Data Minimization and Retention Policies

GDPR mandates that only the minimum necessary data should be collected. Examples of data minimization practices in trials:

• Avoiding unnecessary identifiers (full name, address)
• Using subject IDs instead of real names
• Removing date of birth when year is sufficient

Data should be retained only as long as necessary. For clinical trials, this may be 25 years or more per regulatory guidance, but GDPR still requires a documented retention justification in your Data Protection Impact Assessment (DPIA).

Cross-Border Transfers: EU to US and Beyond

Transferring trial data outside the EU—such as to US-based CROs or cloud storage providers—requires additional safeguards. Under GDPR, this is governed by Chapter V and includes:

• Standard Contractual Clauses (SCCs)
• Binding Corporate Rules (BCRs)
• Adequacy decisions (e.g., Japan, UK)

For U.S. transfers, the EU-U.S. Data Privacy Framework may be applicable (as of July 2023). If relying on SCCs, sponsors must perform a Transfer Impact Assessment (TIA) to evaluate surveillance risks.

Data Subject Rights in the Context of Trials

GDPR grants trial participants (data subjects) several rights:

• Right of access to personal data
• Right to rectification and erasure (“right to be forgotten”)
• Right to restrict processing
• Right to data portability

However, when processing is based on public interest for research (Article 9(2)(j)), some rights may be limited. Sponsors must:

• Document the legal basis clearly in the ICF and privacy notice
• Respond to access or erasure requests within 30 days
• Maintain an electronic log of subject rights requests in the TMF

Refer to EMA GDPR trial guidance for specifics.

Blockchain and GDPR Compatibility Challenges

Blockchain technology provides immutability and decentralized auditability—ideal for maintaining traceability in trials. However, GDPR poses challenges:

• Immutability conflicts with “right to erasure”
• Difficulty in identifying data controllers in decentralized systems
• Blockchain logs may contain personal data (e.g., subject IDs)

Recommended solutions:

• Store only hashes or metadata on-chain, and raw data off-chain
• Use encryption and pseudonymization to minimize re-identifiability
• Conduct DPIA prior to blockchain system deployment

Learn more about compliant blockchain trials at PharmaValidation.in.

Audit Finding: Lack of SCCs for Cloud Storage Vendor

In a 2022 GCP inspection by a European supervisory authority, a CRO was cited for transferring patient data to a cloud provider in a third country without SCCs in place.

Observations included:

• No Data Processing Agreement (DPA) between sponsor and vendor
• Transfers occurred outside documented data flow maps
• No Transfer Impact Assessment (TIA) available

The CAPA included:

• Retroactive SCC execution
• DPO signoff before any cross-border setup
• Re-training of vendor qualification team on GDPR controls

Best Practices for GDPR Compliance in Pharma Trials

• Conduct a DPIA for every study involving EU subjects
• Maintain an up-to-date data inventory and flow map
• Appoint a DPO and register processing with regulators (if required)
• Train staff on responding to data subject requests
• Use privacy-by-design tools in EDC, eTMF, and IRT systems
• File all GDPR documents in TMF under “Regulatory & Privacy”

Conclusion: Integrating GDPR into Trial Lifecycle

GDPR compliance is not a one-time activity—it must be embedded into every phase of the clinical trial lifecycle. From protocol design and informed consent to database lock and archive, every stakeholder must understand their data protection responsibilities.

With the global nature of trials and increasing use of decentralized platforms, aligning with GDPR and related privacy regulations is essential to avoid costly fines and maintain public trust.

For SOPs and templates, visit PharmaSOP.in or refer to ICH E6(R3).